1. 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015;136:E359.
2. 2. Mottet N, van den Bergh R, Briers E, Cornford P, Santis MD, Fanti S, et al. EAU Guidelines on Prostate Cancer. Eur Urol 2019;76:871.
3. 3. Wammack R, Djavan B, Mesut R, Susani M, Marberger M. Morbidity of transrectal ultrasoundguided prostate needle biopsy in patients receiving immunosuppression . Urology 2001;58:1004–7.
4. 4. Wenzel M, Theissen L, Preisser F, Lauer B, Wittler C, Humke C, Bodelle B, Ilievski V, Kempf VAJ, Kluth LA, Chun FKH, Mandel P and Becker A. Complication Rates After TRUS Guided Transrectal Systematic and MRI-Targeted Prostate Biopsies in a High-Risk Region for Antibiotic Resistances. Front. Surg. 2020;7:7.
5. 5. Loeb, S., Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876–92.